Comparative pharmacokinetics of the carbapenems: clinical implications.

摘要: During the last few decades, several carbapenems have been developed. The major characteristic of newer drugs, such as MK-826, is a prolonged half-life. Alternatively, some developed that can be given orally, CS-834 and L-084. Although imipenem panipenem to administered with co-drug prevent degradation by enzyme dehydropeptidase-1 reduce nephrotoxicity, drugs meropenem, biapenem lenapenem are relatively stable towards enzyme. Structural modifications have, besides changes in pharmacology, also led varying antimicrobial properties. For instance, meropenem more active against Gram-negative organisms than most other carbapenems, but slightly less Gram-positive organisms.